Spermidine Promotes Nb CAR-T Mediated Cytotoxicity to Lymphoma Cells Through Elevating Proliferation and Memory

Area of Science:

• Immunology
• Cell Biology
• Cancer Therapy

Background:

• Spermidine, a natural polyamine, possesses immunomodulatory properties.
• Chimeric antigen receptor T (CAR-T) cell therapy shows promise in cancer treatment.
• Enhancing CAR-T cell efficacy is crucial for improving patient outcomes.

Purpose of the Study:

• To investigate the impact of spermidine pretreatment on nanobody-based CAR-T (Nb CAR-T) cell-mediated cytotoxicity.
• To elucidate the mechanisms underlying spermidine's effects on Nb CAR-T cells.
• To assess the potential of spermidine as an adjunct therapy for CAR-T cell treatments.

Main Methods:

• Determined optimal spermidine concentration (5μM) for T cell viability and proliferation.
• Analyzed CAR-T cell phenotype and expansion capacity via flow cytometry and co-culture assays.
• Evaluated in vitro cytotoxicity and cytokine production (IL-2, IFN-γ) upon lymphoma cell stimulation.
• Assessed in vivo anti-tumor activity and survival in xenograft models.

Main Results:

• Spermidine pretreatment significantly increased antigen-dependent proliferation of CAR-T cells.
• Spermidine promoted a central memory T cell (TCM) phenotype in CAR-T cells.
• Enhanced secretion of IL-2 and IFN-γ was observed upon stimulation with lymphoma cells.
• Spermidine-treated CAR-T cells demonstrated improved lysis of tumor cells, even at high tumor burdens.
• In vivo studies showed spermidine-treated Nb CAR-T cells controlled tumor growth and prolonged survival.

Conclusions:

• Spermidine enhances Nb CAR-T cell-mediated cytotoxicity against lymphoma by improving T cell memory and proliferation.
• Spermidine pretreatment offers a promising strategy to augment the anti-tumor efficacy of CAR-T cell therapy.
• This study provides a novel approach to strengthen CAR-T cell therapy for hematological malignancies.